| Autor: |
White Jr., John R. |
| Předmět: |
|
| Zdroj: |
Clinical Diabetes; Spring2008, Vol. 26 Issue 2, p53-57, 5p, 1 Chart |
| Abstrakt: |
This article provides an overview of the pharmacology and clinical use of the dipeptidyl peptidase-IV (DPP-IV) inhibitors. It is claimed that these drugs inhibit the degradation of glucagon-like peptide-1 (GLP-1) in humans and cause some of the same effects of GLP-1, including stimulation of insulin secretion and inhibition of glucagon secretion. It is said that DPP-IV inhibitors offer a safe and effective method for modestly reducing hyperglycemia alone or in combination with other agents in patients with type 2 diabetes. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
